LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock Position Increased by Victory Capital Management Inc.

Key Points

• Victory Capital Management Inc. has increased its stake in LeMaitre Vascular by 45.9%, owning approximately $6.70 million worth of the company's shares.
• LeMaitre Vascular reported $0.48 EPS for the last quarter, slightly missing analyst expectations, but showed a 12.0% year-over-year revenue growth.
• The company recently declared a quarterly dividend of $0.20 per share, with a payout ratio of 40.40%, reflecting commitment to returning value to shareholders.

Victory Capital Management Inc. lifted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 45.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 79,871 shares of the medical instruments supplier's stock after acquiring an additional 25,133 shares during the quarter. Victory Capital Management Inc. owned 0.35% of LeMaitre Vascular worth $6,701,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in LeMaitre Vascular by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier's stock valued at $50,711,000 after purchasing an additional 7,737 shares during the period. Northern Trust Corp boosted its position in LeMaitre Vascular by 5.1% during the 4th quarter. Northern Trust Corp now owns 327,815 shares of the medical instruments supplier's stock valued at $30,205,000 after purchasing an additional 15,843 shares during the period. Envestnet Asset Management Inc. boosted its position in LeMaitre Vascular by 9.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 285,109 shares of the medical instruments supplier's stock valued at $23,921,000 after purchasing an additional 25,680 shares during the period. Price T Rowe Associates Inc. MD boosted its position in LeMaitre Vascular by 0.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 284,779 shares of the medical instruments supplier's stock valued at $26,240,000 after purchasing an additional 1,680 shares during the period. Finally, Invesco Ltd. boosted its position in LeMaitre Vascular by 50.5% during the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock valued at $16,124,000 after purchasing an additional 58,720 shares during the period. Institutional investors and hedge funds own 84.64% of the company's stock.

Insider Transactions at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 76,868 shares of the business's stock in a transaction on Monday, May 19th. The stock was sold at an average price of $85.79, for a total value of $6,594,505.72. Following the sale, the chief executive officer owned 1,796,783 shares of the company's stock, valued at approximately $154,146,013.57. The trade was a 4.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders sold 100,000 shares of company stock worth $8,556,857. Insiders own 9.50% of the company's stock.

LeMaitre Vascular Stock Performance

LMAT stock traded up $0.35 during trading on Monday, reaching $82.78. 44,177 shares of the company's stock were exchanged, compared to its average volume of 188,839. The company has a quick ratio of 13.83, a current ratio of 16.49 and a debt-to-equity ratio of 0.48. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58. The company's fifty day moving average price is $82.59 and its 200-day moving average price is $87.29. The firm has a market cap of $1.87 billion, a PE ratio of 41.90, a P/E/G ratio of 2.17 and a beta of 0.82.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.53% and a net margin of 19.96%. The business had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. During the same quarter last year, the firm posted $0.44 EPS. The company's revenue was up 12.0% compared to the same quarter last year. On average, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were given a dividend of $0.20 per share. The ex-dividend date was Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.97%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 40.40%.

Analyst Ratings Changes

Separately, Barrington Research restated a "market perform" rating on shares of LeMaitre Vascular in a research report on Tuesday, July 22nd. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $97.83.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.